You are here

Home » Content

Periton Diyalizi ve Rezidüel Böbrek Fonksiyonu

Peritoneal Dialysis and Residual Renal Function

Journal Name:

  • Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi

Publication Year:

  • 2007
Author NameUniversity of AuthorFaculty of Author
Bookmark/Search this post with
Abstract (Original Language): 
Kronik böbrek yetmezliği, böbrek işlevinin ilerleyici kaybı ile karakterizedir. Glonıerüler filtrasyon hızının (GFH) azalması, son dönem böbrek yetmezliği gelişimi ile başlanılan diyaliz tedavisi altında da devam eder. Periton diyalizine (PD) başlayan hastalarda yapılan çalışmalar, rezidüel renal fonksiyonun (KRF) giderek azalarak, ortalama 2 yıldan sonra anlamsız düzeylere indiğini göstermiştir (1,2). Rezidüel renal fonksiyonun korunması, diyaliz tedavisine başlamamış kronik böbrek hastalıklı bireylerin tedavisinin birinci! hedefi olmasına karşın, diyaliz hastalarındaki önemi yakın döneme kadar yeterince değerlendirilmemiştir. Bazı araştırmacılar, diyaliz hastalarında RRF'nin hipervolemi pahasına sürdürülen bir işlev olduğunu ve normovolemik durumun sağlanmasının doğal sonucu olarak renal kan akımının ve RRF'nin azalacağını ileri sürmüştür (3,4). Acaba RRF kardİyak yapı ve fonksiyonun korunması ve uzun süreli klinik sonuçların iyileştirilmesi açısından ihmal edilmesi gereken bir işlev midir? Yoksa hemodiyaliz (HD) ile karşılaştırmalı birçok sağkalım çalışmasında (5,6) PD hastalarında 2. yıldan sonra gözlenen relatif mortalile artışının temel nedeni RRF'nin kaybı olabilir ini? Bu yazıda, PD hastalarında RRF'nin önemi tanışılacak ve RRF'yi koruyucu yaklaşımlardan bahsedilecektir.
FULL TEXT (PDF): 
PDF icon arastrmx_172977_16_pp_12-20.pdf
  • 1
12-20
  • Turkish

REFERENCES

References: 

1. Davies SJ, Phillips t-, Russell GI. Peritoneal solute transport predicts .survival on CAPD independently of residual renal function. Nephrol Dial Transplant 1998;13:962-968.
2. Bargman JM, Thorpe KE, Churchill DN; CANUSA Peritoneal Dialysis Study Group. Relative contribution of residual renal function and perilnneal clearance lo adequacy of dialysis: a reanalysis of the CANUSA study. J Am Soc Nephrol 2001;12:2158-2162.
3- Gunal Al, Dunum S, Ozkahya M, el al. Strict volume control normalizes hypertension in peritoneal dialysis patients. Am J Kidney Dis 2001;37:588-593.
4. Gunal Al, Kircnnan li, Güler M, Yavuzkır M. Çelikef H Should the preservation of residual renal function cost volume overload and its consequence left ventricular hypertrophy in new hemodialysis patients? Ren Fail 2004;26:405-109.
5. Foley RN, Parfrey PS, Harnett JD, et al. Mode of dialysis therapy and mortality in end-stage renal disease, J Am Sex: Nephrol 1998;9:267-276.
6. Terniorsliurzen F, Korevaar JC, Dekker FW, Van Manen JG, Boesclioten EW, Krediet RT; The Netherlands Cooperative Study on the Adequacy of Dialysis Study Group. Hemodialysis and peritoneal dialysis: comparison of adjusted mortality rates according lo the duration of dialysis: analysis of The Netherlands Cooperative Study on the Adequacy of Dialysis 2. J Am Soc Nephrol 2003;14:2851-2860.
7. Krediet RT. How to preserve residual renal function in patients with chronic kidney disease and on dialysis^ Nephrol Dial "transplant 2006;21 (Suppl 2):ii42-ii46.
8. Hoek FJ, Korevaar JC, Dekker FW, Boesclioten FW, Krediet RT. Estimation of residual glomerular filtration rate in dialysis patients from the plasma cystalin C. level. Nephrol Dial
18
Türk
Nefroloj
i Diyaliz ve Transplantasyon Dergisi /Official Journal of the Turkish Society of Nephrology
Periton Diyalizi ve Rezidüel Böbrek Fonksiyonu 0
Transplant 2(X>7:22:1633-163».
9. Van Acker HA, Koomen GC, Koopman MG, de Waart DR, Arisz 1.. Creatinine clearance tim ing cimetidine administration for measurement ol' glomerular filtration rate. Lancet 1992^40:1326-1329.
10. Churchill DN, Taylor DW, Kcshaviah PR for the CANUSA Peritoneal Dialysis Study Group. Adequacy of dialysis and nutrition in continuous peritoneal dialysis: Association With clinical outcomes. J Am Soc Nephrol 1996;7:198-207.
11. Termorshuizen F, Korevaar JC. Dekker FW, van Manen JG, Boesclioten FW, Krediet Iff'; NFCOSAD Study Group. The relative importance of residual renal function compared with peritoneal clearance for patient survival and quality of life; an analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NFCOSAD)-2. Am J Kidney Dis 2003;41:1293-1302.
12. Ales K, Nergizoğlu G, Keven K, et al. Effect of fluid and sodium removal on mortality in peritoneal dialysis patients. Kidney hit 2001;60:767-776.
13. Wang AY. Woo J, Wang M, et .if Important differentiation of factors that predict outcome in peritoneal dialysis patients with different degrees of residual renal function. Nephrol Dial Transplant 2005;20:3<>0-itli.
14. Diaz-Buxo JA, Lowrie EG, Leu NL, Zhang SM, Zhu X, Lazarus JM. Associates of"mortality among peritoneal dialysis patients with special reference to peritoneal transport rates and solute clearance. Am .1 Kidney Dis l9^9;33:523-534.
15. Rocco M, Sonde JM, Pastan S. McClellan WM. Peritoneal dialysis adequacy and risk of death. Kidney Int 2000;58:446-457.
16. Shemin 1), liostom AG. Lambert C, Hill C, KİtsenJ, Kliger AS. Residual renal function in a large cohort of peritoneal dialysis patients; change over time, impact on mortality and nutrition. Peril Dial Int 2000;20: İ39- ı ı i
17. Lanı MF, "Lang C, Wong AK, et al. ASPD: A prospective study of adequacy in Asian patients on long-term, small volume, continuous ambulatory peritoneal dialysis. Perit Dial Int 2(106:26:466-474.
IS. Paniagua R. Amato D, Vonesh F, et al; Mexican Nephrology Col la hora I ive Study Group. Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis; ADEMEX. a prospective, randomized, controlled trial. J Am Soc Nephrol 2002;13:1307-1320.
19. \Van» AY, Lai KN. The importance of residual renal function in dialysis patients. Kidney hit 20116;69; 1726-1732.
20. Amid G, Virga G, Da RG, et al. Serum beta.-2-nıieroglobulin level and residual renal function in peritoneal dialysis. Nephron 1993;65:469-471.
21. Bammens B, F.venepocl P. Verbeke K, Vanrenterghem Y. Removal of middle molecules and protein-bound solutes by peritoneal dialysis and relation with uremic symptoms. Kidney hit 2003;64:2238-2243.
22. Bammens B, F.venepoel P, Verbeke K, Vanrenterghem Y. Time profiles of peritoneal and renal clearances of different uremic solutes İn incident peritoneal dialysis patients. Anı J Kidney Dis 2005;46:512-511).
23. Tian X. Wang T. Dissociation between the correlation of peritoneal and urine Kt/V with sodium and fluid removal; A possible explanation of their difference on patient survival. Int Urol Nephrol 2005;37;6l 1-01 i.
24. McConnick BB, Bargman JM. The implications of the ADEMEX study for the peritoneal dialysis prescription: the role of small soluie clearance versus salt and water removal. Curr Opin Nephrol Hypertens 2003;12:581-585.
25. RottemlxHirg J. Residual renal function and recovery of renal
function in patients treated by CAPD. Kidney Int 1993;43(Suppl 40):S106-S110.
26. Enia G, Mallamaci F, Benedetto FA, et al. Long-term CAPD patients are volume expanded and display more severe left ventricular hypertrophy than haemociiatysis patients. Nephrol Dial Transplant 2001;16:1459-1464.
27. Lameire N. Cardiovascular risk factors and blood pressure control in continuous ambulatory peritoneal dialysis. Perit Dial Int 1993;13. Van Biesen W, Veys N. Vanholder R, Lameire N. The role of API) in the improvement of outcomes in an F.SRD program. Semin Dial 2002:15:422-426.
57. Cuelo-Manzano AM, Rojas-CampOS E, Martinez-Ramirez HR, et al. Can the inflammation markers of patients with high peritoneal permeability on continuous ambulatory peritoneal dialysis lx' redused on nocturnal inlermitlenl peritoneal dialysis? Peril Dial lnl 2006;26:341-348.
58. Dittrich E, Puttinger II, Schillinger M, et al. Effect of radio contrast media on residual renal function in peritoneal dialysis
patients - a prospective study. Nephrol Dial Transplant 2006;21:1334-1339. 59- Moranne O, Willoteaux S, Pagniez D, Dequiedl P, Boulanger E. Effect of iodinated contrast agents on residual renal function in PD patients. Nephroi Dial Transplant 2006;21:1040-1045.
60. Shemin D, Maaz D, St Pierre D, Kalın SI, Chazan JA. Effect of aminoglycoside use on residual renal function in peritoneal dialysis patients. Am J Kidney Dis 1999;34:14-20,
61. Lui SL, Cheng SW, Ng F, et al. Cefazoltn plus netilmicin versus cefazolin plus ceftazidime for Healing CAPD peritonitis: Effect on residual renal function. Kidney Int 2005;68:2375-2380.
62. Baker RJ, Senior H, Clemenger M, Brown EA. Empirical aminoglycosides for peritonitis do not affect residual renal function. Am J Kidney Dis 2003;41:670-675.
63. Konings CJ, Kooman JP, Gladziwa LI, van der Sande FM, Leunissen KM. A decline in residual glomerular filtration during the use of icodextrin may be due to underhydrarion. Kidney Int 2005;67:1190-1191.
64. Medcalf JF, Harris KP, Walls J. Role of diuretics in the preservation of residual renal function in patients on continuous ambulatory peritoneal dialysis. Kidney Int 2001;59:1128-1133.
65- van Olden RW, Guchelaar HJ, Struijk DG, Krediet RT, Arisz L. Acute effects of high-dose furosemide on residual renal function in CAPD patients. Perit Dial Int 2003;23:339-347.
66. Li PK, Chow KM, Wong TY, Leung CBT Szeto CC. Effects ol an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving periloneal dialysis. A randomized, controlled study. Ann Intern Med 2003;139:105-112.
67. Suzuki H, Kanno Y, Sugahara S, Okada II, Nakamoto H. Effects of an angiotensin fl receptor blocker, valsanan, on residual renal function in patients on CAPD. Am J Kidney Dis 2004;43:1056-1064.
68. Phakdeekitchharoen B, Leelasa-nguan P. Effects of an ACE inhibitor or angiotensin receptor blocker on potassium in CAPD patients. Am J Kidney Dis 2004;44:738-746.
69. Breborowicz A, Pawlaczyk K, Poiubinska A, et al. Effect of peritoneal dialysis on renal morphology and function. Nephrol Dial Transplant 2006;21:3539-3544.
70. Davies SJ, Woodrow G, Donovan K, et al. Icodextrin improves the fluid status of peritoneal dialysis patients: results of a double-blind randomized controlled trial, j Am Soc Nephrol 2003;14:2338-2344.
71. Adachi Y, Nakagawa Y, Nishio A. Icodextrin preserves residual renal function in patients treated with automated peritoneal dialysis. Perit Dial Int 2006;26:405-407.
72. Konings CJ, Kooman JP, Schonck M, et al. Effect of icodextrin on volume status, blood pressure and echocardiographic parameters: a randomized study. Kidney lnl 2003;63:1556-1563¬73- Williams JD, Topley N, Craig KJ, et al. The Euro-Balance
Trial: The effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int 2004;66:408-418.
74. Montenegro J, Saracho RM, Martinez İM, Munoz RI, Ocharan JJ, Valladares E. Long-term clinical experience with pure bicarbonate peritoneal dialysis solutions. Perit Dial Int 2006;26:89-94.
75. Szeto CC, Chow KM, Lam CW, et al. Clinical biocompatibili-ty of a neutral peritoneal dialysis solution with minimal glucose-degradation products - A 1-year randomized control trial. Nephrol Dial Transplant 2007;22:552-559.

Thank you for copying data from http://www.arastirmax.com